Key clinical point: Survival after 12 months was more likely with transcatheter repair of tricuspid regurgitation instead of guideline-directed medical therapy, and patients were less likely to be rehospitalized with heart failure.
Major finding: Transcatheter repair was associated with greater survival and freedom from heart failure rehospitalization (hazard ratio, 0.60; 95% confidence interval, 0.46-0.79; P = .003).
Study details: A propensity-matched, case-control study with 268 patient pairs.
Disclosures: No company funding was reported. The study lead is a consultant for Abbott Vascular, Boston Scientific, 4TECH, and CoreMedic, and has received speakers fees from Edwards Lifesciences.
Taramasso M et al. J Am Coll Cardiol. 2019 Sep 24. doi: 10.1016/j.jacc.2019.09.028.